Adjunct Therapy for Schizophrenia

Psychosocial Interventions

The American Psychiatric Association recommends cognitive-behavioral therapy for psychosis (CBTp) as a primary adjunct for patients with schizophrenia, to address residual positive symptoms, depression, and improve coping through enhanced adherence and symptom management (1B recommendation) 1, 2, 3, 4
Psychoeducation is strongly recommended (1B) for all patients to increase understanding of illness, treatment options, and relapse prevention strategies 1, 2, 3, 4
Supported employment services should be offered (1B recommendation) to address functional outcomes and quality of life 1, 2, 3, 4
Family interventions are suggested (2B) for patients with ongoing family contact to improve family understanding and coping strategies 1, 2, 4
Assertive community treatment is recommended (1B) for patients with poor engagement history leading to frequent relapse, homelessness, or legal difficulties 1, 2, 3, 4

Clozapine augmentation is the primary pharmacological strategy if the patient develops treatment-resistant schizophrenia despite adequate trials of the current antipsychotic 1, 2, 3, 4
Clozapine is also specifically recommended (1B) if suicide risk remains substantial despite other treatments 1, 2, 3, 4
Mood stabilizers (including antidepressants) may be used to address comorbid mood instability, dysphoria, or depressive symptoms 5
Benzodiazepines can be added for akathisia or agitation management 1, 2, 3, 4
Anticholinergic medications are recommended (1C) for acute dystonia and suggested (2C) for parkinsonism associated with antipsychotic therapy 1, 2, 3, 4
Beta-blockers are suggested (2C) as an option for akathisia 1, 2, 3, 4
VMAT2 inhibitors are recommended (1B) for moderate to severe or disabling tardive dyskinesia 1, 2, 3, 4

The American Psychiatric Association 2020 guidelines do not endorse routine antipsychotic polypharmacy, though real-world practice shows 10-40% of patients receive it 6
Long-acting injectable antipsychotics are suggested (2B) as an alternative formulation if the patient prefers this or has documented poor adherence 1, 2, 3, 4